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Research Article
PSYCHOTHERAPY VERSUS PHARMACOTHERAPY FOR
POSTTRAUMATIC STRESS DISORDER: SYSTEMIC
REVIEW AND META-ANALYSES TO DETERMINE
FIRST-LINE TREATMENTS
Daniel J. Lee, M.D.,1,2 ∗ Carla W. Schnitzlein, D.O.,2,3 Jonathan P. Wolf, M.D.,4 Meena Vythilingam, M.D.,5
Ann M. Rasmusson, M.D.,6,7,8 and Charles W. Hoge, M.D.9

Background: Current clinical practice guidelines (CPGs) for posttraumatic stress
disorder (PTSD) offer contradictory recommendations regarding use of medications or psychotherapy as first-line treatment. Direct head-to-head comparisons are lacking. Methods: Systemic review of Medline, EMBASE, PILOTS,
Cochrane Central Register of Controlled Trials, PsycINFO, and Global Health
Library was conducted without language restrictions. Randomized clinical trials
ࣙ8 weeks in duration using structured clinical interview-based outcome measures, active-control conditions (e.g. supportive psychotherapy), and intent-totreat analysis were selected for analyses. Independent review, data abstraction,
and bias assessment were performed using standardized processes. Study outcomes were grouped around conventional follow-up time periods (3, 6, and 9
months). Combined effect sizes were computed using meta-analyses for medication versus control, medication pre-/posttreatment, psychotherapy versus control,
and psychotherapy pre-/posttreatment. Results: Effect sizes for trauma-focused
psychotherapies (TFPs) versus active control conditions were greater than medications versus placebo and other psychotherapies versus active controls. TFPs
resulted in greater sustained benefit over time than medications. Sertraline, venlafaxine, and nefazodone outperformed other medications, although potential for
methodological biases were high. Improvement following paroxetine and fluoxetine treatment was small. Venlafaxine and stress inoculation training (SIT)
demonstrated large initial effects that decreased over time. Bupropion, citalopram, divalproex, mirtazapine, tiagabine, and topiramate failed to differenti-
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ate from placebo. Aripiprazole, divalproex, guanfacine, and olanzapine failed to
differentiate from placebo when combined with an antidepressant. Conclusions:
Study findings support use of TFPs over nontrauma-focused psychotherapy or
medication as first-line interventions. Second-line interventions include SIT,
and potentially sertraline or venlafaxine, rather than entire classes of medication, such as SSRIs. Future revisions of CPGs should prioritize studies that utilize
active controls over waitlist or treatment-as-usual conditions. Direct head-tohead trials of TFPs versus sertraline or venlafaxine are needed. Depression and

C 2016 Wiley Periodicals, Inc.
Anxiety 33:792–806, 2016.
Key words: PTSD; posttraumatic stress disorder; pharmacotherapy; psychotherapy; VA/DoD; ISTSS; NICE; WHO; Australian; Department of Defense; International Society for the Study of Traumatic Stress; National Institute for Clinical
Excellence; World Health Organization

INTRODUCTION

Current clinical practice guidelines (CPGs) for post-

traumatic stress disorder (PTSD) offer contradictory
recommendations regarding use of medications or psychotherapy as ﬁrst-line treatment despite having basis in common clinical literature.[1–6] Veteran’s Affairs/Department of Defense (VA/DoD), American Psychiatric Association (APA), and International Society for Traumatic Stress Studies (ISTSS) guidelines
present medications and psychotherapy as equivalent
ﬁrst-line treatments.[1, 3, 6] Conversely, National Institute for Clinical Excellence (NICE), Australian, and
World Health Organization (WHO) assert traumafocused psychotherapies (TFPs) are superior to medications, and recommend against medication when TFPs
are available.[2, 4, 5] Methodologically, VA/DoD, APA,
and ISTSS prioritize number of positive trials and
value uncontrolled data whereas other guidelines base
recommendations on larger effects for TFPs against
control.[1–6] Each guideline utilized different review
methodologies and inclusion/exclusion criteria for studies considered.[1–6]
Medication recommendations differ across guidelines
as well.[1–6] VA/DoD experts conclude all selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are roughly
equivalent ﬁrst-line treatments.[1] They advocate use of
prazosin, tricyclic antidepressants (TCAs), monoamine
oxidase inhibitors (MAO-Is), and nefazodone as secondline interventions. ISTSS experts recommend sertraline, paroxetine, ﬂuoxetine, venlafaxine, mirtazapine,
nefazodone, and prazosin for ﬁrst-line use.[3] They
advocate second-line use of phenelzine, amitriptyline,
and bupropion. APA experts conclude SSRIs warrant
ﬁrst-line use, with all other second-generation antidepressants comprising second-line use. NICE experts
ﬁnd paroxetine, sertraline, amitriptyline, and phenelzine
superior to other medications for second-line use.[2]
Australian guidelines recommend SSRIs, and WHO

recommends TCAs and MAO-Is.[4–6] All recommend
against regular use of antiepileptics, antipsychotics, and
benzodiazepines.[1–6] One reason for differing guideline
recommendations is that psychotherapy effects are generally larger than those observed in medication studies.
However, many psychotherapy studies involve waitlist
and treatment-as-usual control conditions that inﬂate
effect sizes, and do not control for time with a provider
and other nonspeciﬁc treatment factors. Active-control
conditions in psychotherapy studies, and particularly
placebo-control in medication trials, tend to narrow efﬁcacy margins between treatment and control conditions.
Discussion of PTSD psychotherapy is complicated
by the term trauma-focused cognitive behavioral therapy (TF-CBT), which has two meanings. When used in
guidelines, TF-CBT generally encompasses both meanings, and is synonymous with TFP, referring collectively
to all types of psychotherapy with trauma-focus, including eye movement desensitization (EMDR), prolonged
exposure (PE), cognitive processing therapy (CPT),
imaginal exposure (IE), as well as a speciﬁc type of TFP
used in some studies. NICE, WHO, Australian, and APA
guidelines recommend TFP/TF-CBTs as a group.[2, 4–6]
VA/DoD guidelines recommend psychotherapy that includes components of exposure or cognitive restructuring such as EMDR, PE, CPT, IE, TF-CBT, or
stress inoculation training (SIT). ISTSS guidelines
highlight EMDR, PE, CPT, and SIT as ﬁrst-line
treatments.[3]
This series of meta-analyses was designed to answer
the primary question of whether TFPs are superior to
medications, or if both are generally equivalent ﬁrstline interventions in adult populations with PTSD. Although several recent expert reviews and meta-analyses
of PTSD treatment have been published, they have
methodological limitations, including unsystematic or
overly stringent inclusion/exclusion criteria or statistical extrapolations made from uncontrolled open-label
data.[7–12] Most, importantly, previous analyses were
Depression and Anxiety
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Figure 1. (A) Generic search strategy (interventions), (B) search strategy (syntax).

not designed to address the core question of whether
TFPs have greater evidence of effectiveness than medications. Our goal in this analysis was to provide rigorous,
transparent, and valid comparisons to inform clinical
practice and improve existing CPGs. We compare
medication and psychotherapy performance against
placebo- or active-control conditions, as well as pre/posttreatment symptom severity using gold-standard
PTSD outcome measures. Based on evidence reviews
in existing CPGs, we hypothesized that psychotherapy
would outperform medications under controlled conditions, due to larger effect sizes observed in these studies,
but would have generally comparable within-group pre/posttreatment improvements, most strongly supporting
VA/DoD and ISTSS guideline recommendations.

METHODS
This report adheres to PRISMA guidelines.[13] Four authors (D.L.,
C.S., J.W., C.H.) searched Medline (1900-July 2015), EMBASE
(1860-July 2015), PILOTS, Cochrane Central Register of Controlled
Trials, PsycINFO (1806-July 2015), and Global Health Library without language restrictions. Our full search strategy is online (Fig. 1A
and B). Search involved combinations of PTSD and generic medication names, psychotherapy names, and psychotherapy abbreviations.
Bibliographies of included studies and guidelines were reviewed for
citations to supplement the search.
Depression and Anxiety

We searched for published and unpublished randomized adult clinical trials of any therapy or medication compared with active/placebocontrol conditions utilizing intention-to-treat analyses. We deﬁned 8
weeks of medication or eight sessions of psychotherapy as the minimum length necessary for inclusion, a broad deﬁnition often used in
health services research.[14] We included every medication for which
we could ﬁnd qualifying studies. Psychotherapy sessions for both treatment and control conditions were required to be individual, in-person,
manualized, and ࣙ45 min in duration. The in-person criterion was required to avoid potentially confounding results due to differences in
nonspeciﬁc effects associated with direct interaction with the therapist in the room. Group therapies were excluded due to their limited evidence, nonspeciﬁc social effects of the group environment, and
clinical challenges delivering core trauma-focused components in this
manner. Psychotherapies deviating from traditional manualized approaches were excluded. For this study, the term “TF-CBT” is used
only to refer to a speciﬁc psychotherapy type and TFPs refer to the
entire group of psychotherapies.
PTSD diagnosis using DSM-III-R or DSM-IV-TR criteria was
required prior to treatment initiation. PTSD trials with 100% prevalence of comorbid conditions, such as borderline personality disorder,
primary thought disorder, or substance use disorder were excluded as
these were not generalizable to standard patient populations. However, many studies included samples with high percentages of comorbid substance abuse, depression, and anxiety disorders at rates typical
of PTSD study populations. Gold standard, interview-based outcome
measures required for inclusion were Clinician-Administered PTSD
Scale (CAPS), Short PTSD Rating Interview (SPRINT), and PTSD
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Figure 1. Continued.

Symptom Scale-Interview (PSS-I), which have been validated against
the Structured Clinical Interview for DSM-IV and CAPS and widely
adopted in PTSD research. Outcome measures created for speciﬁc
RCTs or validated as part of an RCT design were excluded. These
included standardized interview for PTSD (SI-PTSD), revised standardized interview for PTSD (SIP), and several outcome measures
named for Duke University.[15–18]
Study outcomes were grouped by follow-up duration (8–12 weeks,
14–27 weeks, and 32+ weeks) and consolidated into overall effect using
meta-analysis. Our intent was to separate outcome measures into traditional 3-, 6-, and 9-month end points as a surrogate for performance
over time. Selected ranges allowed for capture of outcome measurements occurring at or closely around these time points. Outcomes
beyond 32 weeks were grouped together due to variable end points.
Many medication trials longer than 12 weeks involved maintenance
(continuing medication after response) and relapse prevention (determining if switch to placebo after response causes loss of efﬁcacy). Both

designs were retained because they began from similar baselines and
their exclusion would have eliminated most long-term medication trials. Although most psychotherapy trials involved weekly treatment, if
treatment was provided more or less frequently, outcomes collected
immediately posttreatment were included within the 8- to 12-week
grouping. Later measures were grouped normally.
Given the paucity of psychotherapy studies that excluded concomitant medications, we allowed psychotherapy trials in which participants
were taking medications, provided these were similar for treatment
and control. All included medication studies involved placebo control.
Medication studies wherein >25% of the study population was maintained on an antidepressant were considered adjunctive trials as they
differed signiﬁcantly from monoagent trials requiring discontinuation
of all other medications. Psychotherapy controls included supportive psychotherapy, biofeedback, and relaxation training. Waitlist and
treatment-as-usual controls were deemed insufﬁcient to account for
nonspeciﬁc treatment effects and were excluded.
Depression and Anxiety
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For studies meeting above inclusion criteria, we avoided exclusions
based on study quality or risk of bias, since differing inclusion/exclusion
criteria appeared to be a major factor in variation between guideline
recommendations. Most importantly, exclusion of studies deemed at
high risk of bias would have resulted in exclusion of most medication trials; we prioritized answering our research question, even if this
meant inclusion of biased studies.

STUDY SELECTION AND DATA ABSTRACTION
We utilized a two-stage study selection process. In stage one, four
authors (D.L., C.S., J.W., C.H.) independently reviewed titles and
abstracts to select full text articles. If based on abstract or title, a
study was determined to be randomized, but study length or session
number could not be determined (or vice versa), we erred toward retrieval. If neither could be determined, it was excluded. During stage
two, D.L. and C.S., J.W., M.V., A.R., or C.H. independently applied
inclusion/exclusion criteria using standardized forms, assessed article
quality using Cochrane’s bias assessment tool,[19] and extracted data.
Interrater agreement was high for these measures (>95%). Disagreements centered on handling of unanticipated outcome measures and
psychotherapy controls and were resolved by consensus. Extracted demographic information appears in Table 1.

STATISTICAL ANALYSIS
Meta-regression was considered, but rejected in favor of metaanalysis, which was deemed more accurate for nonlinear data and time
intervals driven by clinical convention. Due to differences between
CAPS, SPRINT, and PSS-I, we computed study effect sizes to determine overall effect size for each intervention. By convention, effect
sizes greater than 0.8 are considered large, those between 0.6 and 0.8
moderate, and those between 0.2 and 0.5 small.[20] Performance versus control was computed using treatment and control measures taken
at the same time. Pre-/posttreatment analyses compared treatment
group measures against group baseline. Guideline comparisons were
done by combining effects for all ﬁrst-line or second-line interventions
recommended in the guidelines using meta-analysis. For example, the
VA/DoD guideline recommends SSRIs and SNRIs as ﬁrst-line pharmacological treatments, and TFT or SIT as ﬁrst-line psychotherapies.
Thus, we ran separate meta-analyses involving the various combinations of studies using these different ﬁrst-line treatments.
Studies analyzing different aspects of the same study population
were combined into a single study for analysis. Studies with multiple treatment arms measured against a single active-control condition
were analyzed as separate studies (e.g., PE vs. interpersonal therapy
(IPT) vs. control became PE vs. control and IPT vs. control). All uncontrolled data points were excluded. Data points were excluded if they
involved exclusion of treatment responders or treatment nonresponders. Heterogeneity was assessed using the I2 statistic, though large
heterogeneity was expected due to inclusion of many interventions
(Fig. 2).[21] We estimated number of unpublished trials needed to invalidate our ﬁndings using ﬁle drawer/fail safe (FDFS).[22] All analyses
were completed using Stata’s metan command (v.11). Meta-analyses
utilized inverse variance weighting with random effects.

RESULTS
Of 61,268 initial search results, 285 potential articles were identiﬁed, retrieved, and assessed for eligibility (Fig. 3). Sixty-three articles met inclusion criteria;
seven of these articles[23–29] described outcomes from
three research populations. These results were combined into three studies, leaving 58 independent studies. Three studies replicated data from other included
Depression and Anxiety

studies, leaving 55 total studies. Interventions that met
inclusion criteria and number of studies using them included aripiprazole (1),[30] brofaromine (2),[31, 32] bupropion (1),[33] TF-CBT (2),[23, 24, 34] citalopram (1),[35] CPT
(1),[36] divalproex (2),[37, 38] EMDR (2),[39, 40] ﬂuoxetine
(5),[25, 26, 41–44] guanfacine (2),[45, 46] IPT (1),[47] mirtazapine (1),[16] nefazodone (1),[48] olanzapine (3),[18, 49, 50]
paroxetine (7),[51–57] PE with cognitive restructuring
(PE/CR) (2),[58, 59] PE (7),[40, 47, 58–62] prazosin (3),[63–65]
risperidone (5),[66–70] sertraline (5),[27–29, 35, 71–73] SIT
(1),[60] tiagabine (2),[17, 74] topiramate (2),[75, 76] and venlafaxine (2).[71, 77]
A total of 6,313 participants were enrolled across all
trials (Table 1). Average study duration was 18 weeks
(range 8–104) with the average medication study running 17 weeks (8–64) and the average psychotherapy
study running ten sessions (8–12). A mean of 115 participants (10–551) took part in each study. Forty-nine percent of participants were women (0–100%). Mean age of
participants was 42 (30–55). All included studies were in
English. Thirty-one medication trials (72%) were industry supported. Average percentage of veterans was 40%
(0–100%). Dropout average was 29% (0–79%). In 36
studies specifying major depressive disorder prevalence
at initiation, average comorbidity was 41% (0–86%).
QUALITY AND RISK OF BIAS

Quality varied, with most studies having important
limitations in design, reporting, or both (Table 2).
Double-blinding was not possible for psychotherapy
studies, and it is unlikely nonspeciﬁc placebo effects
were fully controlled for, even with optimal methods.
Nevertheless, psychotherapy trials were generally better
designed, executed, and reported than medication
studies. Cochrane criteria demonstrated considerable
differences in risk of bias between medication and
psychotherapy studies (Table 2). Most psychotherapy trials were rated low or very low risk of bias
and most medication trials were rated high or very
high risk of bias, despite the fact they were placebo
controlled. Differences were noted for allocation
concealment, adherence, sequence generation, and
industry sponsorship, suggesting fundamental design and reporting differences. A typical medication
study was conducted by one of a handful of industrysponsored researchers, selectively reported data, and
failed to disclose methods for randomization, allocation concealment, or adherence. Failure to perform
pill counts, having treating providers assess outcome
measures, and nonrandom group assignments allowed
possible inﬂuence toward desired outcomes. Randomization and blinding success were also questionable
in some medication studies with groups differing
signiﬁcantly in adverse effects and attrition, which
could easily jeopardize allocation concealment. Data
reporting, standardized across psychotherapy studies,
varied across medication studies, particularly among
industry-sponsored trials. Most medication studies and
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TABLE 1. Demographic information for included studies
Intervention
Aripiprazole
Brofaromine
Brofaromine
Bupropion
CPT
Divalproex
Divalproex
EMDR
EMDR, PE, PE/CR
Fluoxetine
Fluoxetine
Fluoxetine
Fluoxetine
Fluoxetine
Guanfacine
Guanfacine
IE, IE/CR
Mirtazapine
Nefazodone
Olanzapine
Olanzapine
Olanzapine
Paroxetine
Paroxetine
Paroxetine
Paroxetine
Paroxetine
Paroxetine
Paroxetine
PE
PE
PE, IPT
PE, PE/CR
PE, SIT
Prazosin
Prazosin
Prazosin
Risperidone
Risperidone
Risperidone
Risperidone
Risperidone
Sertraline

Sertraline
Sertraline
Sertraline, citalopram
Sertraline, venlafaxine
TF-CBT
TF-CBT
TF-CBT
Tiagabine
Tiagabine
Topiramate
Topiramate
Venlafaxine

Author
(year)

Mean dose/
No. of sessions

N

Veterans (%)

Women (%)

Mean age

Depression %

Naylor (2015)
Baker (1995)
Katz (1995)
Becker (2007)
Suris (2013)
Davis (2008)
Hamner (2009)
Carlson (1998)
Taylor (2003)
Davidson (2005)
Martenyi (2007)
Martenyi (2002),
Martenyi (2002)
Martenyi (2006)
van der Kolk (2007)
Davis (2008)
Neylan (2006)
Bryant (2003)
Davidson (2003)
Davis (2004)
Butterﬁeld (2001)
Carey (2012)
Stein (2002)
GlaxoSmithKline (2001)
Marshall (2001)
Marshall (2007)
Schneier (2012)
Tucker (2000)
Fani (2009)
Fani (2011)
Schnurr (2007)
Rauch (2014)
Markowitz (2015)
Marks (1998)
Foa (1991)
Raskind (2007)
Raskind (2013)

16
118
45
28
86
85
29
35
60
123
411
301

100
60
18
50
0
100
100
100
0
32
5
31

31
19
24
21
85
Uncertain
3
0
75
50
72
19

34
44
39
50
46
55
52
48
37
44
41
38

86
Uncertain
0
Uncertain
Uncertain
Uncertain
69
Uncertain
42
Uncertain
Uncertain
0

10 mg
Uncertain
Uncertain
300 mg
10 sessions
2309 mg
1196 mg
Uncertain
8 sessions
49 mg
30 mg
57 mg

144
59
35
56
58
29
41
15
28
21
263
551
52
37
323
18
13
284
30
110
87
45
38
67

100
0
100
100
0
14
98
60
0
100
0
8
0
0
7
Uncertain
8
100
100
0
3
0
100
100

1
83
6
Uncertain
52
50
2
93
61
0
66
67
67
54
66
56
54
100
8
77
36
100
5
15

36
36
53
Uncertain
35
47
54
43
41
53
43
42
40
50
41
41
40
45
32
40
38
32
56
30

0
Uncertain
57
Uncertain
Uncertain
73
39
53
0
Uncertain
0
45
63
66*
35
Uncertain
85
64*
47
50
49
Uncertain
Uncertain
34

Raskind (2003)
Padala (2006)
Reich (2004)
Bartzokis (2004)
Krystal (2011)
Rothbaum (2008)
Brady (2000), Davidson
(2001), Davidson
(2001)
Friedman (2007)
Zohar (2002)
Tucker (2003)
Davidson (2006)
Blanchard (2003),
Blanchard (2003)
McDonaugh (2005)
Ehlers (2014)
Connor (2005)
Davidson (2007)
Tucker (2007)
Yeh (2011)
Davidson (2006)

10
20
21
65
296
20
385

100
0
0
100
100
0
5

0
100
100
0
3
80
76

53
41
28
52
54
34
38

Uncertain
Uncertain
62
Uncertain
70
80
37

65 mg
30 mg
2 mg
2 mg
Uncertain
39 mg
435 mg
14 mg
9 mg
15 mg
Uncertain
30 mg
Uncertain
32 mg
28 mg
Uncertain
Uncertain
9 sessions
11 sessions
8 PE/13 IPT
Uncertain
Uncertain
13 mg
20 mg men / 9 mg
women
10 mg
3 mg
1 mg
3 mg
3 mg
2 mg
139 mg

169
42
58
531
98

100
100
3
9
0

20
12
74
Uncertain
73

46
40
39
Uncertain
40

0
0
78
0
49

74
121
26
232
40
35
329

0
0
4
9
0
0
12

100
59
73
66
79
68
54

40
39
41
43
42
40
41

Uncertain
36
Uncertain
38
61
13
0

135 mg
120 mg
Sert 134 mg/cit 36 mg
Sert 110 mg/ven 164 mg
10 sessions
Uncertain
12 sessions
11 mg
11 mg
150 mg
103 mg
182 mg

CPT, cognitive processing therapy; EMDR, eye movement desensitization reprocessing therapy; IE, imaginal exposure; PE, prolonged exposure;
PE/CR, prolonged exposure with cognitive restructuring; SIT, stress inoculation training; TF-CBT, trauma-focused cognitive behavioral therapy.
∗ Reporting of mood disorder rather than depression.
Depression and Anxiety
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Figure 2. I2 statistic.

several psychotherapy studies reported outcome data
selectively or in a misleading manner. Examples included partial/nonstandard reporting between text and
charts,[19, 20, 22–27, 32–35, 37–39, 42, 44–46, 49, 52, 56, 58, 60, 62, 63, 65–69]
switching
between
mean/mean
change,[25, 26, 38, 43–45, 48, 50, 52, 66, 69, 71–75] switching be-

tween standard deviations(SD)/conﬁdence intervals/standard
errors,[25, 26, 28, 30, 43, 44, 51, 55, 62, 64, 67, 71, 72]
omitting baseline outcome data,[28, 33, 68] omitting variance measures completely,[28, 31, 68] omitting outcome
measures at speciﬁc time points,[28, 40, 68] creation of
nonstandard outcome measures by combining standard
measures with other variables,[25, 28, 32, 41, 44, 51, 73] splitting
outcome measures into subscales without providing total
score,[39, 58] failure to cross-reference data spread over
several publications,[25, 26, 43, 44] and including nonscaled
graphs without providing corresponding means.[28, 40, 68]
Data abstraction for most medication studies required
mathematical conversion of provided data into mean total CAPS/SPRINT/PSS-I and SD. Data extraction for

Figure 3. Flow of Studies, Reasons for nonretrieval or exclusion involved one or more of the following: (1) not pertinent to research
question, (2) duration was too short, (c) wrong outcome measure(s), and/or (d) study involved acute stress disorder or subdiagnostic
PTSD.
Depression and Anxiety
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TABLE 2. Application of Cochrane bias assessment to all included studies
Bias risk

Intervention

Very low
Very low
Very low
Very low
Very low
Very low
Very low
Low

CPT
IE, IE/CR
PE, PE/CR
PE
PE
TF-CBT
Topiramate
TF-CBT

Low
Low
Low
Low

TF-CBT
EMDR
EMDR, PE
Fluoxetine

Low
Low
Low
Low
Moderate
Moderate
Moderate
Moderate
Moderate
High
High
High
High
High
High
High
High
High
High

Fluoxetine
PE, SIT
Prazosin
Divalproex
Fluoxetine
Paroxetine
PE
Divalproex
Guanfacine
Brofaromine
Brofaromine
Bupropion
Fluoxetine
Mirtazapine
Nefazodone
Paroxetine
Prazosin
Prazosin
Sertraline

High
High
High
High
High
High
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high
Very high

Sertraline
Sertraline
Olanzapine
Topiramate
Aripiprazole
Guanfacine
Fluoxetine
Paroxetine
Paroxetine
Paroxetine
Sertraline, Citalopram
Sertraline, Venlafaxine
Venlafaxine
Olanzapine
Tiagabine
Tiagabine
Paroxetine
Paroxetine
Risperidone
Risperidone
Olanzapine
Risperidone
Risperidone
Risperidone

Author
(year)

Dropout
(%)

Adherence

Sequence
generation

Allocation
concealment

Industry
support

Selective
reporting

Suris (2013)
Bryant (2003)
Marks (1998)
Schnurr (2007)
Markowitz (2015)
Ehlers (2014)
Yen (2011)
Blanchard (2003),
Blanchard (2003)
McDonaugh (2005)
Carlson (1598)
Taylor (2003)
Martenyi (2002),
Martenyi (2002)
Martenyi (2005)
Foa (1991)
Raskind (2007)
Davis (2008)
van der Kolk (2007)
Schneier (2012)
Rauch (2014)
Hamner(2009)
Neylan (2006)
Baker (1995)
Katz (1995)
Becker (2007)
Davidson (2005)
Davidson (2003)
Davis (2004)
Marshall (2007)
Raskind (2013)
Raskind (2003)
Brady (2000), Davidson
(2001), Davidson
(2001)
Friedman (2007)
Zohar (2002)
Carey (2012)
Tucker (2007)
Naylor (2015)
Davis (2008)
Martenyi (2007)
GlaxoSmithKline (2001)
Marshall (2001)
Tucker (2000)
Tucker (2003)
Davidson (2006)
Davidson (2006)
Butterﬁeld (2001)
Connor (2005)
Davidson (2007)
Fani (2009)
Fani (2011)
Padala (2006)
Reich (2004)
Stein (2002)
Bartzokis (2004)
Krystal (2011)
Rothbaum (2008)

28
22
60
29
25
3
26
20

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Uncertain

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No
No
No
No

No
No
Yes
No
No
No
No
Yes

23
3
35
61

Yes
Yes
Yes
Yes

Uncertain
Uncertain
Uncertain
Yes

Yes
Yes
Yes
Yes

No
No
No
Yes

Yes
Yes
Yes
No

67
18
18
20
34
41
28
48
10
30
27
23
44
31
44
42
39
0
79

No
Yes
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Yes
Yes
Uncertain
Uncertain
Uncertain
Yes
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Yes

Yes
Uncertain
Yes
Yes
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Yes
Yes
Uncertain
Uncertain
Uncertain

No
No
No
No
No
No
No
Yes
No
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
Yes

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

24
26
29
5
25
19
12
51
37
39
24
34
32
27
50
61
44
0
0
0
10
26
17
44

Uncertain
Yes
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Insufﬁcient
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain

Yes
Uncertain
Yes
Yes
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain

Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain
Uncertain

Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

CPT, cognitive processing therapy; EMDR, eye movement desensitization reprocessing therapy; IE, imaginal exposure; PE, prolonged exposure;
PE/CR, prolonged exposure with cognitive restructuring; SIT, stress inoculation training; TF-CBT, trauma-focused cognitive behavioral therapy.
All trials with ITT design. All therapy trials unblinded and all medication trials were blinded.
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two studies[28, 68] were particularly problematic; neither
mean total CAPS nor baseline total CAPS were provided. Each required us to estimate CAPS and variance
from a nonscaled graph. Several attempts to obtain data
from Pﬁzer and Janssen were unsuccessful, forcing us
to use our best estimate. Request for the second negative Pﬁzer study submitted to the FDA in support of
a PTSD indication for sertraline was also unsuccessful. Psychotherapy data requests, in contrast, were returned promptly. Estimates based on FDFS suggested
that 12,581 unpublished trials with no effect would be
required to reduce controlled ﬁndings to statistical insigniﬁcance and 51,639 would be required to invalidate
pre-/posttreatment ﬁndings.
EFFICACY TRENDS

Pre-/Posteffects for Monoagent Pharmacotherapy and Psychotherapy. Pre-/post comparisons
across treatments demonstrated large effects for both
medications and psychotherapy, which generally increased over time when follow-up data were included
(Tables 3 and 4). Pre-/posteffect sizes for TFPs were
larger than individual medications and medication
groupings (i.e. SSRIs), and was particularly notable
9 months or more after psychotherapy was initiated.
Most adjunctive pharmacotherapy studies failed to show
beneﬁt.
Efficacy of Monoagent Pharmacotherapy and Psychotherapy versus Controls. When compared with
control, effect sizes were uniformly lower than those
observed in pre-/postcomparisons. TFPs clearly outperformed individual and medication groupings and
nontrauma-focused psychotherapies (non-TFPs) across
the diverse group of psychotherapies including PE/IE,
PE/CR, CPT, EMDR, and TF-CBT (Tables 3 and 4).
PE/IE demonstrated the most consistent effects across
time. Addition of cognitive techniques to PE appeared to
make it less effective, although outcomes at ﬁnal followup were consistent with PE alone. CPT and TF-CBT
also demonstrated moderate-to-large effect sizes across
time. EMDR demonstrated an effect size comparable
to other trauma-focused therapies, but failed to reach
signiﬁcance at the ﬁnal time-point, likely due to being underpowered. SIT demonstrated large initial effect
with diminishing effects beyond 12 weeks. IPT never
achieved signiﬁcance versus active-control condition.
Medications demonstrating large effects were sertraline,
venlafaxine, and nefazodone.
Brofaromine, bupropion, citalopram, monoagent
and adjunctive divalproex, mirtazapine, risperidone,
tiagabine, topiramate, adjunctive aripiprazole, adjunctive guanfacine, and adjunctive olanzapine never
achieved signiﬁcance against control. Paroxetine and
ﬂuoxetine both performed poorly against control.
Antiepileptics as a class failed to achieve signiﬁcance.
Antipsychotics as a class demonstrated small effects, but
this conclusion is limited by the myriad of side effects
and high risk of study bias.
Depression and Anxiety

Adjunctive Pharmacotherapy. Prazosin was the
only medication to demonstrate large effect and only at
14–27 weeks.
Comparison of Guidelines. When studies were
grouped by guideline recommendations for ﬁrst and
second-line interventions, guidelines considering psychotherapy superior to medications (Australian, WHO,
NICE) outperformed guidelines considering psychotherapy and medications equivalent (ISTSS, APA,
VA/DoD) (Table 4). Guidelines recommending both
demonstrated lower effects than those restricting ﬁrstline interventions to TFPs. ISTSS, APA, and VA/DoD
guideline recommendations performed similarly, with
the exception of ISTSS recommendations showing
larger effects at 14–27 weeks due to inclusion of prazosin as a ﬁrst-line intervention. Second-line interventions performed poorly across all guidelines.

DISCUSSION
This is the most comprehensive set of meta-analyses
comparing psychotherapy and medication efﬁcacy for
PTSD, and determining which speciﬁc treatments warrant ﬁrst-line recommendations. Only psychotherapy
trials involving active-control conditions were included,
mirroring as closely as possible placebo-control conditions used in medication trials.
By every measure considered in this study, TFPs
were superior to medications. In general, large reductions in gold-standard outcomes persisted long after
psychotherapy completion, whereas continued use of
medication was necessary for long-term beneﬁts. These
ﬁndings are further strengthened considering the requirement for active-control conditions and many advantages medication studies had in participant enrollment, industry involvement and funding, and likelihood
of bias toward more positive outcomes in medication trials (e.g. methodological bias or prioritizing recruitment
of patients with lower comorbidities or less prior treatment). Our ﬁndings suggest that medications largely act
by blunting expression of symptoms of PTSD, rather
than acting on critical neurobiological mechanisms underlying, for example, extinction of conditioned fear
responses, which is a primary target of exposure and
cognitive-based TFPs.
Concerning guideline recommendations, our ﬁndings
suggest PTSD treatment guidelines need revision. Clinicians should be educated on the priority of TFPs, and
many changes are required in medication recommendations. For example, our ﬁndings suggest patients who
experience partial responses to medication treatment
should be referred for TFP rather than being prescribed
a second medication. Superiority of the broad class of
TFPs over SIT or IPT suggests working directly with
trauma in some form leads to better outcomes, although
this conclusion is limited by the fact that only two studies directly compared non-TFPs with another activecontrol condition. For individuals too avoidant or autonomically activated to engage in TFP, SIT, sertraline, or

−1.42 (−1.93 to −0.92)
−3.72 (−4.09 to −3.35)
−2.37 (−3.27 to −1.47)
−1.49 (−2.53 to −0.45)
−2.08 (−2.53 to −1.63)

Adjunctive pharmacotherapy (used with an antldepressant)
−0.03 (−1.08 to 1.02)
0.38 (−0.36 to 1.12)
−0.11 (−0.51 to 0.29)
−0.8 (−1.73 to 0.14)
−2.19 (−2.76 to −1.63)
−0.38 (−1.06 to 0.30)
−1.22 (−1.46 to −0.97)
−0.19 (−0.98 to 0.6)

−0.97 (−2.08 to 0.13)
0.08 (−0.63 to 0.8)
−0.37 (−0.78 to 0.04)
−0.8 (−1.71 to 0.11)
−0.62 (−1.31 to 0.07)
−1.16 (−1.96 to −0.36)

Aripiprazole
Divalproex
Guanfacine
Olanzapine
Prazosin
Risperidone

−1.94 (−2.38 to −1.50)

−4.38 (−4.80 to −3.96)
−2.49 (−3.12 to −1.85)

Psychotherapy
−8.61 (−9.84 to −7.38)
−2.12 (−3.28 to −0.96)

−1.01 (−1.46 to −0.56)
−0.49 (−0.71 to −0.28)

−0.25 (0.77 to 0.27)
−1.03 (−1.24 to −0.82)
−0.38 (−1.14 to 0.38)
−0.40 (−1.33 to 0.53)
−0.83 (−1.21 to −0.45)

−1.22 (−1.69 to −0.75)

−0.32 (−0.54 to −0.10)

0.11 (−0.82 to 1.04)

0.09 (−0.67 to 0.86)

14–27 wk vs. control

−0.69 (−1.07 to −0.31)

−0.80 (−1.03 to −0.57)
−1.50 (−2.22 to −0.78)

−0.57 (−1.01 to −0.13)
−1.12 (−2.41 to 0.16)

−1.46 (−1.91 to −1.01)

−0.08 (−0.38 to 0.21)

−0.10 (−0.35 to 0.15)

−0.60 (−1.20 to 0.00)

34+ wk vs. Control

Wk, weeks; pre/post, pre-/post-treatment; TF-CBT, trauma-focused cognitive behavioral therapy; CPT, cognitive processing therapy; EMDR, eye movement desensitization reprocessing; IE,
imaginal exposure; IPT, interpersonal therapy; PE/CR, prolonged exposure with cognitive restructuring; PE, prolonged exposure; SIT, stress inoculation training.
All pre-/post-treatment changes calculated using initial baseline for treatment group. Red highlighting signiﬁes nonsigniﬁcance. Green highlighting signiﬁes a large effect. Nonhighlighted boxes
signify small or moderate effect.

−7.20 (−8.25 to −6.15)

−1.08 0 (−1.54 to −0.62)
−0.87 (−1.42 to −0.32)
−0.15 (−0.67 to 0.37)
−1.01 (−1.20 to −0.83)
−0.41 (−0.88 to 0.06)
−1.26 (−2.12 to −0.40)
−0.39 (−0.70 to −0.08)

−6.71 (−7.70 to −5.72)
−2.06 (−2.72 to −1.41)
−0.95 (−1.42 to −0.48)
−2.57 (−2.83 to −2.31)
−1.54 (−2.05 to −1.03)
−2.75 (−4.04 to −1.46)
−1.37 (−1.7 to −1.03)

−2.34 (−2.73 to −1.96)

Missing data

−0.07 (−0.37 to 0.22)
−0.22 (−1.12 to 0.68)
0.18 (−0.56 to 0.91)
−0.03 (−0.46 to 0.41)
−0.23 (0.39 to −0.07)
−0.81 (−1.65 to 0.02)
−1.32 (−2.02 to −0.63)
−0.72 (−1.36 to −0.09)
−0.36 (−0.49 to −0.28)
−0.48 (−1.1 to 0.14)
−0.51 (−0.64 to −0.38)
0.02 (−0.24 to 0.28)
−0.34 (−0.82 to 0.14)
−1.78 (−2.01 to −1.52)

CPT
EMDR
IPT
PE/IE
PE/CR
SIT
TF−CBT

−2.45 (−2.74 to −2.16)

−3.28 (−4.33 to −2.23)

−1.67 (−2.47 to −0.86)

−2.60 (−2.88 to −2.32)

−1.53 (−2.14 to −0.92)

Monoagent pharmacotherapy
34+ Wk pre/post
8–12 wk vs. control

−1.30 (−1.62 to −0.98)
−1.11 (−1.88 to −0.34)
−1.54 (−2.17 to −0.91)
−0.69 (−1.14 to −0.25)
−1.46 (−1.57 to −1.34)
−1.23 (−1.97 to −0.50)
−0.86 (−1.43 to −0.30)
−2.00 (−2.69 to −1.31)
−1.35 (−1.49 to −1.22)
−1.35 (−2.00 to −0.71)
−1.49 (−1.64 to −1.34)
−2.47 (−2.81 to −2.12)
−2.12 (−2.70 to −1.54)
−3.78 (−4.12 to −3.43)

14–27 wk pre/post

Brofaromine
Bupropion
Citalopram
Divalproex
Fluoxetine
Mirtazapine
Nefazodone
Olanzapine
Paroxetine
Risperidone
Sertraline
Tiagabine
Topiramate
Venlafaxine

8-12 wk pre/post

TABLE 3. Comparative table of effect sizes (95% CIs) calculated using CAPS/SPRINT/PSS-I grouped by time
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−1.67 (−2.47 to −0.86)
−2.36 (−2.63 to −2.09)
−3.28 (−4.33 to −2.23)
−1.22 (−1.46 to −0.97)
−4.10 (−4.45 to −3.75)
−3.84 (−4.17 to −3.51)
−3.26 (−3.52 to −3.00)
−1.43 (−1.89 to −0.98)
−2.80 (−3.03 to −2.58)
−2.36 (−2.59 to −2.13)
−2.17 (−2.30 to −2.03)
First-line interventions
−3.11 (−3.36 to −2.86) −2.84 (−3.01 to −2.67)
−3.26 (−3.52 to −3.00) −3.28 (−3.54 to −3.02)
−3.23 (−3.50 to −2.96) −3.06 (−3.26 to −2.87)
−2.95 (−3.16 to −2.74) −3.48 (−3.75 to −3.22)

−1.43 (−1.51 to −1.36)
−1.54 (−1.61 to −1.46)
−1.65 (−1.89 to −1.42)
−1.36 (−1.71 to −1.01)
−2.74 (−2.97 to −2.50)
−2.74 (−2.97 to −2.51)
−2.19 (−2.37 to −2.01)
−1.16 (−1.60 to −0.72)
−2.04 (−2.21 to −1.88)
−1.50 (−1.56 to −1.43)
−1.54 (−1.60 to −1.48)

−1.54 (−1.61 to −1.47)
−2.19 (−2.37 to −2.01)
−1.63 (−1.70 to −1.55)
−1.65 (−1.73 to −1.58)

−3.32 (−3.63 to −3.01)
−1.43 (−1.51 to −1.36)
−1.11 (−1.88 to −0.34)
−1.35 (−1.48 to −1.22)
−1.12 (−1.37 to −0.88)

SSRIs Only
SSRIs + SNRIs
All Antiepileptics
All Antipsydiotics
EMDR+PE/IE + CPT
EMDR + PE/IE + CPT+SIT
All trauma-focused therapies
All nontrauma-focused therapies
All therapies
All medications
All interventions

APA
Australian, NICE, and WHO
ISTSS
VA/DoD

APA
Australian and WHO
ISTSS
NICE
VA/DoD

−1.53 (−2.14 to −0.92)

−0.51 (−1.16 to 0.15)
−0.37 (−0.45 to −0.29)
−0.22 (−1.12 to 0.68)
−0.37 (−0.49 to −0.24)
−0.33 (−0.57 to −0.08)

−0.48 (−0.55 to −0.41)
−0.83 (−0.97 to −0.69)
−0.51 (−0.59 to −0.44)
−0.59 (−0.66 to −0.52)

−0.37 (−0.45 to −0.29)
−0.50 (−0.58 to −0.43)
−0.03 (−0.22 to 0.17)
−0.49 (−0.83 to −0.15)
−1.01 (−1.20 to −0.83)
−1.02 (−1.18 to −0.85)
−0.83 (−0.97 to −0.69)
−0.45 (−0.89 to −0.01)
−0.79 (−0.93 to −0.66)
−0.43 (−0.49 to −0.36)
−0.50 (−0.56 to −0.44)

8–12 wk vs. control

0.09 (−0.67 to 0.86)
−1.03 (−1.54 to −0.52)

−0.32 (−0.54 to −0.10)
0.90 (−0.67 to 0.86)

−0.91 (−1.08 to −0.75)
−0.96 (−1.13 to −0.80)
−1.24 (−1.38 to −1.10)
−0.70 (−0.84 to −0.56)

0.90 (−0.67 to 0.86)
−0.29 (−0.50 to −0.08)
0.11 (−0.82 to 1.04)
−0.49 (−0.71 to −0.28)
−1.03 (−1.24 to −0.82)
−1.03 (−1.22 to −0.84)
−0.96 (−1.13 to −0.80)
−0.29 (−0.74 to 0.17)
−0.90 (−1.06 to −0.74)
−0.44 (−0.58 to −0.30)
−0.64 (−0.75 to −0.54)

14–27 wk vs. control

−0.08 (−0.38 to 0.21)
−0.60 (−1.20 to 0.00)

−0.30 (−0.47 to −0.12)

−0.52 (−0.65 to −0.40)
−0.75 (−0.92 to −0.57)
−0.44 (−0.55 to −0.32)
−0.48 (−0.62 to −0.34)

−0.79 (−0.96 to −0.62)
−0.32 (−0.49 to −0.15)
−0.55 (−0.67 to −0.43)

−0.80 (−1.03 to −0.57)
−0.80 (−1.03 to −0.57)
−0.75 (−0.92 to −0.57)

−0.30 (−0.47 to −0.12)
−0.30 (−0.47 to −0.12)

34+wk vs. control

CPT, cognitive processing therapy; EMDR, eye movement desensitization reprocessing; IE, imaginal exposure; PE, prolonged exposure; SIT, stress inoculation training; SNRI, serotonin
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; APA, American Psychiatric Association; ISTSS, International Society for Traumatic Stress Studies; NICE,
National Institutes for Clinical Excellence; VA/DoD, Veteran’s Association/Department of Defence; WHO, World Health Organization.
All pre-/posttreatment changes calculated using initial baseline for treatment group. Red highlighting signiﬁes nonsigniﬁcance. Green highlighting signiﬁes a large effect. Nonhighlighted boxes
signify small or moderate effect.

−1.67 (−2.47 to −0.86)
−2.19 (−2.76 to −1.63)

Second-line interventions
−2.45 (−2.74 to −2.16)
−1.67 (−2.47 to −0.86) −2.51 (−2.14 to −2.82)

−3.28 (−3.54 to −3.02)
−2.39 (−2.60 to −2.18)
−2.75 (−2.91 to −2.58)

−4.54 (−4.91 to −4.16)
−4.54 (−4.91 to −4.16)
−3.28 (−3.54 to −3.02)

−2.51 (−2.14 to −2.82)
−2.51 (−2.14 to −2.82)

14–27 wk pre/post

8–12 wk pre/post

Sub meta-analyses
34+ wk pre/post

TABLE 4. Comparative table of effect sizes (95% CIs) of various groupings
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venlafaxine appeared to be the most viable alternatives,
with caveats noted below.
Our ﬁndings contradict conventional wisdom and prescribing patterns, particularly in the United States. Our
analysis demonstrated psychotherapy and medication
are not equivalent, and not all SSRIs or SNRIs are
alike. Our study provides strong evidence against the
theory that PTSD involves a seizure-like kindling phenomenon; antiepileptics were noneffective. Our study
also provides evidence against common U.S. practice of
utilizing antipsychotics in PTSD treatment.
Concerning second-line interventions, our ﬁnding
that sertraline, venlafaxine, and nefazodone outperformed other medication treatments comes with important caveats. Although sertraline appeared to gain efﬁcacy compared with control over time, this ﬁnding was
driven by a single industry sponsored trial with selectively reported data and high risk of bias.[28] Pﬁzer did
not provide data from a second sertraline trial that was
negative. Although venlafaxine demonstrated a large initial effect, this appeared to diminish beyond 12 weeks.
Nefazodone performed strongly in the short term, but
incurs the risk of liver failure.
Adjunctive medication treatment showed lack of efﬁcacy, with the exception of prazosin. However, this ﬁnding is driven by studies from a single research group
with irregular study endpoints (15 and 20 weeks).[63, 64]
Furthermore, a recent large multicenter trial of prazosin
failed to differentiate from placebo in the primary global
change score outcome, and PTSD-speciﬁc outcomes
have still not been published 3 years since completion of
recruitment.[78] Most adjunctive trials, including the prazosin studies, involved treatment-resistant PTSD, which
is a population on which little research has been done.
It is possible that individuals with treatment-resistant
PTSD fundamentally differ from those participating in
most of our included research studies, although this is
currently unclear.

STRENGTHS AND LIMITATIONS

Strengths of this study include the methodological
rigor in data abstraction and analyses and presentation of data simultaneously for controlled and pre/posttreatment effects. We believe excluding medication trials without placebo-controls and psychotherapy
studies relying on waitlist or treatment-as-usual controls
was critically important in addressing our primary scientiﬁc question, although this reduced analyzable studies.
Limitations included relatively few medication studies
extending beyond 12 weeks (reducing analyzable longterm data), few psychotherapy studies running eight or
more sessions using active-control conditions and goldstandard outcome measurements (many studies were excluded), small sample sizes in many studies (widening
conﬁdence intervals), differing study designs (increasing
heterogeneity), and fundamental differences in bias between medication and psychotherapy studies.
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Other limitations included concomitant use of psychotropics in some medication and psychotherapy studies, and incomplete or misleading reporting of data.
Concomitant psychotropics could not be controlled for
as they were present in nearly every study analyzed.
There are also limitations in generalizing clinical trials data to normative clinical populations, in part because selection of study participants is unable to fully
account the stepped manner in which PTSD treatments
are often utilized.[79] The high rate of prior psychotropic
treatment in many clinical trials, for example, could reﬂect a select subset of the PTSD population that has already received some degree of medical stabilization that
has prepared them for engagement in trauma-focused
psychotherapy.[79] However, since disease chronicity is
lower and proportion of treatment naı̈ve patients higher
in industry-sponsored pharmacotherapy trials compared
with psychotherapy trials, one would expect biases in the
direction favoring medications, rather than the results
we observed. Although not systematically analyzed, psychotherapy interventions appeared to outperform medications overall for both treatment naı̈ve samples as well as
samples with high rates of prior or current psychotropic
treatment.
Our decision to group studies by time may have introduced bias into our analysis, although this is unlikely.
A small correlation effect was introduced by using the
same control group twice for the multiarmed studies; this
method did not impact results as overall data remained
unchanged when individual arms or the entire study was
excluded. Each study demonstrated its own idiosyncratic
inclusion and exclusion criteria, which resulted in unavoidable differences in study populations. Comorbidities, previous treatment, and rates of substance abuse
varied. Analyzing these studies as a group presumably
minimizes the impact of individual differences. PTSD
symptom duration was not reported by most studies and
could not be analyzed. Outcome measure standardization resulted in different treatment conclusions for some
studies than reported by their authors.
Although these analyses represent the highest level
of evidence available for medications, they should not
be used to compare effect sizes between different TFPs
due to exclusion of psychotherapy trials without activecontrol conditions, including several important trials
that compared different TFPs head-to-head. The very
large pre-/posteffects for CPT in this meta-analysis were
driven by a single study,[36] and the mildly inferior performance of TF-CBT and EMDR compared with other
TFPs is likely an artifact of inclusion/exclusion criteria and small samples. Individual TFPs have generally
been found equivalent in head-to-head trials. Due to
our study design, we cannot make recommendations
for individual TFPs or comment on individual versus
group TFP; these remain areas for further study. Additionally, these analyses standardized comparisons across
studies using mean effects, and recommendations do
not fully address heterogeneity of underlying pathophysiological mechanisms contributing to differences
Depression and Anxiety
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in individual risk, severity, chronicity, or response to
treatment.
5.

CONCLUSIONS
For future research, greater rigor and consistency in
design and reporting of outcomes is necessary across
studies to prevent biases. Medication trials, in particular,
would beneﬁt from rigorous head-to-head comparisons
against FDA-indicated medications such as sertraline or
paroxetine, or TFPs, in addition to placebo comparisons.
Reduction in the inﬂuence of industry sponsorship is
critical. Well-controlled head-to-head studies of TFPs
versus medication are needed, as are studies of combinations of TFP with sertraline or venlafaxine or other
medications that could potentially facilitate efﬁcacy of
TFPs in relatively refractory patients.
Our ﬁndings contradict several aspects of VA/DoD,
NICE, ISTSS, WHO, Australian, and APA CPGs for
treatment of PTSD, and suggest a need for reconsideration of current guideline recommendations. Guidelines could be improved by focusing on TFPs as the
preferred ﬁrst-line intervention, with sertraline and venlafaxine taking an adjunctive or secondary role. Guidelines should also begin discouraging use of polypharmacy for PTSD. Future research should focus on ways
of tailoring treatment to individual patients to improve
response and retention rates.
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